CARLSBAD, CA--(Marketwire - August 16, 2012) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company focused on therapeutic and research products, today announced the addition of Professor Evan Snyder* and Dr. Rosasio Sánchez-Pernaute as scientific advisors on our Parkinson's disease program.
Evan Snyder, MD, PhD is a Professor at the Sanford-Burnham Medical Research Institute and director of Sanford-Burnham's stem cell program and research center. Prof. Snyder is regarded as one of the pioneers of stem cell research, particularly with regard to regenerative medicine applications. He is an expert on Parkinson's disease (PD), one of the first scientists to identify neural stem cells and to document the ability of stem cells to migrate to injured or diseased regions of the brain. Prof. Snyder is a recipient of an Early Translational Award from the California Institute for Regenerative Medicine (CIRM) to research into cell based therapies for PD.
Rosario Sánchez-Pernaute, MD, PhD is an internationally recognized expert on the use of stem cells to treat Parkinson's disease. While Assistant Professor in Neurology at Harvard Medical School Dr. Sánchez-Pernaute was one of the first scientists to demonstrate the possibility of using parthenogenetic stem cells to treat the causes of PD in a non-human primate model.
"We are extremely fortunate to work with two of the world's leading experts in Parkinson's disease and stem cell research," say Dr. Ruslan Semechkin, Vice President of Research and Development, "Prof. Snyder and Dr. Sánchez-Pernaute will add invaluable expertise to our Parkinson's disease program and provide input into our first non-human primate pre-clinical study which uses the most reliable and predictive model of Parkinson's in humans."
*Prof. Snyder's position is honorary.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
Safe harbor statement
Statements pertaining to anticipated developments, scientific program and clinical development goals and plans and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.